Comparing BZAM (OTCMKTS:BZAMF) & Exagen (NASDAQ:XGN)

Exagen (NASDAQ:XGN) and BZAM (OTCMKTS:BZAMF) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, dividends, earnings and risk.

Insider and Institutional Ownership

75.3% of Exagen shares are owned by institutional investors. Comparatively, 0.0% of BZAM shares are owned by institutional investors. 10.4% of Exagen shares are owned by insiders. Comparatively, 8.7% of BZAM shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and target prices for Exagen and BZAM, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	1	0	8	1	2.90
BZAM	0	0	0	0	0.00

Exagen currently has a consensus price target of $9.11, indicating a potential upside of 98.93%. Given Exagen’s stronger consensus rating and higher possible upside, research analysts clearly believe Exagen is more favorable than BZAM.

Profitability

This table compares Exagen and BZAM’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Exagen	-29.49%	-94.37%	-28.96%
BZAM	N/A	N/A	N/A

Earnings and Valuation

This table compares Exagen and BZAM”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$66.57 million	1.66	-$19.95 million	($0.89)	-5.15
BZAM	N/A	N/A	N/A	($0.27)	N/A

BZAM has lower revenue, but higher earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than BZAM, indicating that it is currently the more affordable of the two stocks.

Summary

Exagen beats BZAM on 7 of the 11 factors compared between the two stocks.

About Exagen

Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

About BZAM

BZAM Ltd. operates as a cannabis producer with a focus on branded consumer goods. Its brands include the BZAM, TGOD, ness, Highly Dutch Organic, and TABLE TOP, as well as Dunn Cannabis, FRESH, and Wyld partner brands. The company operate facilities in British Columbia, Alberta, Ontario, and Quebec, as well as retail stores in Winnipeg, Manitoba and Regina, Saskatchewan. The company was formerly known as The Green Organic Dutchman Holdings Ltd. and changed its name to BZAM Ltd. in February 2023. The company was incorporated in 2016 and is headquartered in Vancouver, Canada.